(19)
(11) EP 4 045 048 A1

(12)

(43) Date of publication:
24.08.2022 Bulletin 2022/34

(21) Application number: 19949416.2

(22) Date of filing: 14.10.2019
(51) International Patent Classification (IPC): 
A61K 31/4985(2006.01)
 A61K 9/22(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/4985; A61K 31/155; A61K 9/2054; A61K 9/2009
 
C-Sets:
  1. A61K 31/4985, A61K 2300/00;
  2. A61K 31/155, A61K 2300/00;
(86) International application number:
PCT/TR2019/050865
(87) International publication number:
WO 2021/076066 (22.04.2021 Gazette 2021/16)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(71) Applicant: Santa Farma Ilaç Sanayi A.S.
34382 Istanbul (TR)

(72) Inventors:
  • YILDIRIM, Ersin
    41455 Dilovas /Kocaeli (TR)
  • KANIK, Bayram
    41455 Dilovas /Kocaeli (TR)
  • ÖZTÜRK, Fatma
    41455 Dilovas /Kocaeli (TR)
  • AKTA , Tansel
    41455 Dilovas /Kocaeli (TR)
  • ÜNLÜ, Celil
    41455 Dilovas /Kocaeli (TR)

(74) Representative: Bulut, Pinar 
Farmapatent Limited GMK Bulvari No: 42/5 Maltepe
06440 Ankara
06440 Ankara (TR)

   


(54) ORAL FORMULATIONS COMPRISING SITAGLIPTIN HCI MONOHYDRATE WITH IMPROVED PHARMACEUTICAL CHARACTERISTICS